Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

Posted: February 24, 2023 at 12:14 am

Advanced RLY-4008: Reported interim data with 88% overall response rate at pivotal dose and 63% across all doses in pan-FGFR treatment-naïve, FGFR2-fusion cholangiocarcinoma patients & announced anticipated registrational path

Read more here:
Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

Related Posts